| Literature DB >> 34778176 |
Tegan J Reeves1, Taylor J Mathis1, Hailey E Bauer1, Melissa M Hudson1,2, Leslie L Robison1, Zhaoming Wang1,3, Justin N Baker2, I-Chan Huang1.
Abstract
The five-year survival rate of childhood cancer has increased substantially over the past 50 yr; however, racial/ethnic disparities in health outcomes of survival have not been systematically reviewed. This scoping review summarized health disparities between racial/ethnic minorities (specifically non-Hispanic Black and Hispanic) and non-Hispanic White childhood cancer survivors, and elucidated factors that may explain disparities in health outcomes. We used the terms "race", "ethnicity", "childhood cancer", "pediatric cancer", and "survivor" to search the title and abstract for the articles published in PubMed and Scopus from inception to February 2021. After removing duplicates, 189 articles were screened, and 23 empirical articles were included in this review study. All study populations were from North America, and the mean distribution of race/ethnicity was 6.9% for non-Hispanic Black and 4.5% for Hispanic. Health outcomes were categorized as healthcare utilization, patient-reported outcomes, chronic health conditions, and survival status. We found robust evidence of racial/ethnic disparities over four domains of health outcomes. However, health disparities were explained by clinical factors (e.g., diagnosis, treatment), demographic (e.g., age, sex), individual-level socioeconomic status (SES; e.g., educational attainment, personal income, health insurance coverage), family-level SES (e.g., family income, parent educational attainment), neighborhood-level SES (e.g., geographic location), and lifestyle health risk (e.g., cardiovascular risk) in some but not all articles. We discuss the importance of collecting comprehensive social determinants of racial/ethnic disparities inclusive of individual-level, family-level, and neighborhood-level SES. We suggest integrating these variables into healthcare systems (e.g., electronic health records), and utilizing information technology and analytics to better understand the disparity gap for racial/ethnic minorities of childhood cancer survivors. Furthermore, we suggest national and local efforts to close the gap through improving health insurance access, education and transportation aid, racial-culture-specific social learning interventions, and diversity informed training.Entities:
Keywords: childhood cancer survivor; ethnicity; health disparities; health outcomes; race
Mesh:
Year: 2021 PMID: 34778176 PMCID: PMC8586515 DOI: 10.3389/fpubh.2021.741334
Source DB: PubMed Journal: Front Public Health ISSN: 2296-2565
Figure 1PRISMA diagram of study selection. Adapted from (21).
Characteristics of studies included in the scoping review.
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|
| Armstrong et al. ( | 0–18 | SEER | NHB (8.8); H (14.4) | Survival rates | All-cause mortality; non-recurrence/non-external mortality | |
| Arpawong et al. ( | 11–21 | Treatment Center | Hispanic (English 27.6; ESL, 19.1) | Patient-reported outcomes | Post-traumatic growth, post-traumatic stress | |
| Barrera et al. ( | 8–16 | Canadian Children's | Black (5.4) | Patient-reported outcomes | Quality of life and emotional quality of life | |
| Berkman et al. ( | 0–34 | SEER | Black (10.7) | Chronic health conditions and survival rates | Cardiovascular conditions, overall mortality | |
| Castellino et al. ( | ≥18 | CCSS | Hispanic (15.6) | Healthcare utilization, patient-reported outcomes | Screening, mental health | |
| Choudhary et al. ( | 2–36 | Sloan Kettering | Black (12.1); Hispanic (15.6) | Chronic health conditions | Vitamin-D deficiency i.e. chemiluminescent assay | |
| Daly et al. ( | >6 | CHOA | 48.5% Non-White | Healthcare utilization | Initial visit | |
| Gance-Cleveland et al. ( | 6–21 | Survivor Clinic | Black (2.4); Hispanic (29.9) | Chronic health conditions | Obesity | |
| Kehm et al. ( | 0–19 | SEER | NHB (11.8); Hispanic (31.5) | Survival rates | Overall survival | |
| Liu et al. ( | 8–58 | CCSS | NHB (5); Hispanic (5.4) | Survival rates and chronic health conditions | Cardiovascular condition, overall mortality | |
| Lu et al. ( | 18–38 | CCSS | NHB (4.3); Hispanic (1.9) | Patient-reported outcomes | Pain | |
| Meeske et al. ( | 8–18 | CHLA | Hispanic (48%) | Patient-reported outcomes | Total and psychosocial function | |
| Meeske et al. ( | 14–25 | CSP | Hispanic (US, 12.9; foreign born 43.8) | Patient-reported outcomes | Parent post-traumatic stress, depression | |
| Milam et al. ( | 14–25 | LA SEER | Hispanic (54.4) | Healthcare utilization | Follow-up care | |
| Miller et al. ( | ≥15 | LA SEER | Hispanic (54.4) | Healthcare utilization | Healthcare self-efficacy | |
| Miller et al. ( | ≥15 | LA SEER | Hispanic (54.4) | Healthcare utilization | Information seeking | |
| Oikonomou et al. ( | 0–19 | SEER | Black (10.7); Other (8.1) | Chronic health conditions | Cardiovascular condition | |
| Raghubar et al. ( | 5–21 | CHLA | Hispanic (29.8); Other (19.2) | Patient-reported outcomes | Adaptive functioning | |
| Samaan et al. ( | 0–19 | SEER | Non-White (17.8) | Survival rates | Mortality to incidence ratio and relative survival trend | |
| Santacroce et al. ( | 37.9 | Clinic | Black (33.3) | Patient-reported outcomes | Uncertainty, anxiety, stress | |
| Tobin et al. ( | 14–25 | CSP | Hispanic (56.2) | Patient-Reported outcome | Post-traumatic growth | |
| Wasilewski-Masker et al. ( | 12.1 | CHOA | Black (14) | Chronic health condition | Severity of symptoms (CTCEA) | |
| Zebrack et al. ( | ≥18 | CCSS | Non-White (6.4) | Patient-reported outcomes | Positive impact |
Less than 5 years since last treatment;
No information on years since last treatment;
Parent responses;
Mean age reported in years at survey/assessment; Reference Group: Non-Hispanic White.
CCSS, Childhood Cancer Survivor Study; CHLA, Children's Hospital of Los Angeles; CHOA, Childhood Healthcare of Atlanta; CHOC, Children's Hospital of Orange County; CSP, Los Angeles Cancer Surveillance Program; SEER, Surveillance Epidemiology and End Results Program.
Factors influencing disparities in healthcare utilization for childhood cancer survivors by race/ethnicity.
|
|
|
|
|
|
|---|---|---|---|---|
|
| ||||
| ( | SES (insurance, education, household income), age, diagnosis |
| OR = 0.7; 95% CI: 0.5–1.0 (males) | Lower general medical contact attenuated by risk modulators. |
| ( | SES (insurance, education, household income), age, diagnosis |
| Lower general medical contact accounting for risk modulators. | |
| ( | Gender, age, treatment factors (year and age of diagnosis, diagnosis, therapy subsequent event), and logistic factors (insurance, distance from clinic) |
|
| Less likely to have initial survivorship visit. |
|
| ||||
| ( | SES (insurance, education, household income), age, diagnosis |
| Lower general medical contact accounting for risk modulators. | |
| ( | SES (insurance, education, household income), age, diagnosis | OR = 1.7, 95% CI: 1.2–2.3 (males) | More likely to visit cancer center accounting for risk modulators. | |
| ( | Age, sex, social support, family influence, post traumatic growth, depressive symptoms, treatment, self-efficacy | OR = 0.55, 95% CI: 0.25–1.21, | Less likely to report previous use of follow-up care after accounting for risk modulators. | |
| ( | Age, sex, social support, family influence, post traumatic growth, depressive symptoms, treatment, self-efficacy | β = −0.38 (0.19), | Lower health-care self-efficacy after accounting for risk modulators. | |
| ( | Age, sex, health insurance | Less likely to get information from hospital. | ||
| ( | Age, sex, health insurance | OR = 0.50, 95% CI: 0.23–1.09, | Less likely to get information from family attenuated by risk modulators. | |
Bold denotes statistical significance with p < 0.05; Reference group Non-Hispanic White or Caucasian; * Reference group listed as Non-Hispanic. SES, Socioeconomic Status; HR, Hazards Ratio; OR, Odd Ratio.
Factors influencing disparities in patient-reported outcomes for childhood cancer survivors by race/ethnicity.
|
|
|
|
|
|
|---|---|---|---|---|
|
| ||||
| ( | SES (insurance, education, household income), age, diagnosis | OR = 0.8; 95% CI: 0.5–1.2 |
| Less adverse mental health after accounting for risk modulators. |
| ( | SES (insurance, education, household income), age, diagnosis |
| OR = 1.2; 95% CI: 0.8–1.8 (females) | Higher functional impairment attenuated by risk modulators. |
| ( | None | Higher reports of pain or abnormal sensation without accounting for risk modulators. | ||
| ( | None | Higher reports of migraines without accounting for risk modulators. | ||
| ( | None | Higher reports of other frequent headaches without accounting for risk modulators. | ||
| ( | Higher parental uncertainty without accounting for risk modulators. | |||
|
| ||||
| ( | None | Higher reports of pain or abnormal sensations without accounting for risk modulators. | ||
| ( | None | Higher reports of other frequent headaches without accounting for risk modulators. | ||
| ( | Demographics, disease/treatment factors, depressive symptoms, PTSS, optimism, QOL, SES | Lower Post-traumatic Growth (PTG) accounting for risk modulators. | ||
| ( | Diagnosis and fatigue | Lower psychosocial health after accounting for risk modulators. | ||
| ( | Diagnosis and fatigue | Lower total reported quality of life after accounting for risk modulators. | ||
| ( | Diagnosis and fatigue | Lower school functioning accounting for risk modulators. | ||
| ( | Diagnosis and fatigue | Lower emotional functioning accounting for risk modulators. | ||
| ( | Birthplace, education, income, stress, and treatment intensity | Higher parent post-traumatic stress. | ||
| ( | Birthplace, education, income, stress, and treatment intensity | Higher rates of depression. | ||
| ( | Family-level SES (parent education and family income) | Lower global adaptive functioning attenuated by risk modulators. | ||
| ( | Family-level SES (parent education and family income) | Lower conceptual adaptive functioning attenuated by risk modulators. | ||
| ( | Family-level SES (parent education and family income) | Lower social adaptive functioning attenuated by risk modulators. | ||
| ( | Family-level SES (parent education and family income) | Lower practical adaptive functioning attenuated by risk modulators. | ||
| ( | Age, sex, social support, family influence, PTG, depressive symptoms, treatment, self-efficacy |
| Higher post-traumatic growth scores accounting for risk modulators. | |
|
| ||||
| ( | Family income and caregiver education |
| Lower emotional quality of life accounting for risk modulators. | |
| ( | Diagnosis and fatigue | Lower psychosocial functioning after accounting for risk modulators. | ||
| ( | Diagnosis and fatigue | Lower total reported quality of life after accounting for risk modulators. | ||
| ( | Diagnosis and fatigue | Lower school functioning accounting for risk modulators. | ||
| ( | Demographic and clinical variables | More positive impact of cancer in all five aspects of growth accounting for risk modulators. | ||
Bold denotes statistical significance with p <0.05; Reference group Non-Hispanic White or Caucasian;
Listed as Other or both Non-Hispanic Black and Hispanic. SES, Socioeconomic Status; PTS, Post Traumatic Stress; QOL, Quality of Life; HR, Hazards Ratio; OR, Odd Ratio.
Factors influencing disparities in chronic health conditions for childhood cancer survivors by race/ethnicity.
|
|
|
|
|
|
|---|---|---|---|---|
|
| ||||
| ( | Pubertal status |
|
| More likelihood of vitamin-D deficiency |
| ( | Diagnosis and fatigue | OR = 2.06, 95% CI: 0.26 = 11.85, | Higher risk of obesity accounting for risk modulators. | |
| ( | Clinical/demographic variables | Higher rate of subsequent neoplasms accounting for risk modulators. | ||
| ( | Clinical/demographic variables and treatment | Higher rate of subsequent neoplasms accounting for risk modulators. | ||
| ( | Clinical/demographic variables, treatment, and SES (education, income, & insurance) | Higher rate of subsequent neoplasms accounting for risk modulator. | ||
| ( | Clinical/demographic variables, treatment, SES (education, income, & insurance), and CVRF (obesity, diabetes, hypertension, and dyslipidemia) | Higher rate of subsequent neoplasms accounting for risk modulators. | ||
| ( | Clinical/demographic variables | Higher grade cardiovascular conditions accounting for risk modulators. | ||
| ( | Clinical/demographic variables and treatment | Higher grade cardiovascular conditions accounting for risk modulators. | ||
| ( | Clinical/demographic variables, treatment, and SES (education, income, & insurance) | Higher grade cardiovascular conditions accounting for risk modulators. | ||
| ( | More or less that years of diagnosis | HR = 0.98, 95% CI: 0.52–1.86, | Higher cardiovascular after five years accounting for risk modulators. | |
| ( | Treatment, diagnosis, age and gender | RR = 0.9, 95% CI: 0.7–1.2, | Higher severity (Grade 3-4) in health conditions after accounting for risk modulators. | |
|
| ||||
| ( | Pubertal status |
|
| More likelihood of vitamin-D deficiency. |
| ( | Diagnosis and fatigue |
| Higher risk of obesity accounting for risk modulators. | |
| ( | Clinical/demographic variables, treatment, SES (education, income, & insurance), and CVRF (obesity, diabetes, hypertension, and dyslipidemia) | Higher rate of subsequent neoplasms accounting for risk modulators. | ||
| ( | Clinical/demographic variables, treatment, and SES (education, income, & insurance) | Increased risk for endocrine conditions accounting for risk modulators. | ||
| ( | Clinical/demographic variables, treatment, SES (education, income, & insurance), and CVRF (obesity, diabetes, hypertension, and dyslipidemia) | Increased risk for endocrine conditions accounting for risk modulators. | ||
Bold denotes statistical significance with p < 0.05; Reference group Non-Hispanic White or Caucasian. CVRF, Cardiovascular Risk Factor; SES, Socioeconomic Status; HR, Hazards Ratio; OR, Odd Ratio; RR, Relative Ratio.
Factors influencing disparities in survival for childhood cancer survivors by race/ethnicity.
|
|
|
|
|
|
|---|---|---|---|---|
|
| ||||
| ( | US mortality rates, sex, year of diagnosis |
| Higher all-cause mortality risk accounting for risk modulators. | |
| ( | US mortality rates, sex, year of diagnosis |
| Higher mortality risk of subsequent malignancy accounting for risk modulators. | |
| ( | Age at diagnosis, time since diagnosis, cancer type |
|
| Higher risk of any death. |
| ( | Age at diagnosis, time since diagnosis, cancer type |
| Age 0–14 HR = 1.08, 95% CI: 0.62–1.89 | Higher cardiovascular disease death attenuated by risk modulators. |
| ( | Clinical/demographic variables | Higher all-cause relative mortality rate accounting for risk modulators. | ||
| ( | Clinical/demographic variables and treatment | Higher all cause relative mortality rate accounting for risk modulators. | ||
| ( | Clinical/demographic variables, treatment, and SES (education, income, & insurance) | RR = 1.0, 95% CI: 0.8–1.4, | Higher all-cause relative mortality rate accounting for risk modulators. | |
| ( | Clinical/demographic variables, treatment, and SES (education, income, & insurance) | Higher all-cause standardized mortality rate accounting for risk modulators. | ||
| ( | Clinical/demographic variables, treatment, and SES (education, income, & insurance) and SVRF (obesity, diabetes, hypertension, and dyslipidemia) | Higher all-cause standardized mortality rate accounting for risk modulators. | ||
|
| ||||
| ( | Clinical/demographic variables, treatment, and SES (education, income, & insurance) and SVRF (obesity, diabetes, hypertension, and dyslipidemia) | Higher all-cause standardized mortality rate accounting for risk modulators. | ||
|
| ||||
| ( | Neighborhood-level SES index | Higher hazard of death for Acute Myeloid Leukemia survivors. | ||
| ( | Neighborhood-level SES index | Indirect HR = 1.08, 95% CI: 0.98–1.20, | Higher hazard of death for Astrocytoma survivors attenuated by risk modulators. | |
| ( | Neighborhood-level SES index | Indirect HR = 1.09, 95% CI; 0.97 | Higher hazard of death for non-astrocytoma CNS tumors attenuated by risk modulators. | |
| ( | None | Higher mortality to incidence without accounting for risk modulators. | ||
Bold denotes statistical significance with p < 0.05; Reference group Non-Hispanic White or Caucasian;
Listed as other or Non-White;
Tract SES Index, National Cancer Institute Census Tract-level socioeconomic status (SES) Index. CVRF, Cardiovascular Risk Factor; SES, Socioeconomic Status; HR, Hazards Ratio; OR, Odd Ratio. SMR, Standard Mortality Ration; RR, Relative Ratio; MIR, Mortality to Incidence Ratio.